The FTC made headlines by issuing a Policy Statement concerning improper Orange Book Listings and using the FDA's regulatory dispute process to challenge over 60 patents and 100 listings from several brand manufacturers in the Orange Book. Please join this panel of experts, including dispute letter signatory Rahul Rao from the FTC and four antitrust practitioners, for a lively discussion.
The content of this program does not meet requirements for continuing legal education (CLE) accreditation. You will not receive CLE credit for participating.